9N3Q image
Entry Detail
PDB ID:
9N3Q
Keywords:
TRANSFERASE/INHIBITOR
Title:
Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 51
Biological Source:
Source Organism:
Homo sapiens
Host Organism:
Trichoplusia ni
PDB Version:
Deposition Date:
2025-01-31
Release Date:
2025-03-12
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
2.54 Å
R-Value Free:
0.26
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 21 21 2
9N3Q validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Description:Protein arginine N-methyltransferase 5
Chain IDs:A, C
Chain Length:645
Number of Molecules:2
Biological Source:Homo sapiens
UniProt ID:O14744 Pfam ID:PF17285, PF05185, PF17286 EC:2.1.1.320
Protein Blast
Polymer Type:polypeptide(L)
Description:Methylosome protein 50
Chain IDs:B, D
Chain Length:350
Number of Molecules:2
Biological Source:Homo sapiens
UniProt ID:Q9BQA1 Pfam ID:PF00400 EC:2.1.1.320
Ligand Molecules
A1BV2
EDO
MTA
Primary Citation
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion.
J.Med.Chem. 68 5097 5119 (2025)
PMID: 40035511 DOI: 10.1021/acs.jmedchem.4c03067

Abstact

The gene encoding for MTAP is one of the most commonly deleted genes in cancer, occurring in approximately 10-15% of all human cancer. We have previously described the discovery of TNG908, a brain-penetrant clinical-stage compound that selectively targets MTAP-deleted cancer cells by binding to and inhibiting PRMT5 cooperatively with MTA, which is present in elevated concentrations in MTAP-deleted cells. Herein we describe the discovery of TNG462, a more potent and selective MTA-cooperative PRMT5 inhibitor with improved DMPK properties that is selective for MTAP-deleted cancers and is currently in Phase I/II clinical trials.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
9N3Q